1207456-00-5

Basic information

• Product Name: BMN 673 (8R,9S)
• Synonyms: (8R,9S)-BMN-673;BMN 673 (8R,9S);BMN673 (8R,9S);BMN-673 (8R,9S);(8R,9S)-5-fluoro-8-(4-fluorophenyl)-9-(1-Methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;(8R,9S)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one;(8R,9S)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-Methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one;3H-Pyrido[4,3,2-de]phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8R,9S)-
• CAS NO: 1207456-00-5
• Molecular Formula: C₁₉H₁₄F₂N₆O
• Molecular Weight: 380.3508664
• Product Categories: API
• Mol File: 1207456-00-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.63±0.1 g/cm3(Predicted)
• Solubility: ≥38 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥15.03 mg/mL in EtOH with gentle warming and ultrasonic
• PKA: 10.14±0.60(Predicted)
• CAS DataBase Reference: BMN 673 (8R,9S)(CAS DataBase Reference)
• NIST Chemistry Reference: BMN 673 (8R,9S)(1207456-00-5)
• EPA Substance Registry System: BMN 673 (8R,9S)(1207456-00-5)

Safety Data

• Hazardous Substances Data: 1207456-00-5(Hazardous Substances Data)

Usage

General Description

BMN 673 (8R,9S) is a chemical compound that belongs to the class of poly ADP-ribose polymerase (PARP) inhibitors. It is a potent and selective inhibitor of PARP enzymes, which play a crucial role in repairing DNA damage. By inhibiting PARP, BMN 673 (8R,9S) prevents the repair of DNA breaks, leading to the accumulation of DNA damage and ultimately leading to cell death, particularly in cells with defects in other DNA repair pathways, such as those found in certain types of cancer. This makes BMN 673 (8R,9S) a promising candidate for the development of targeted cancer therapies, particularly for tumors with specific DNA repair deficiencies.

Upstream product

• 1207454-56-5 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 459-57-4 4-fluorobenzaldehyde 
• 1322879-81-1 methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate 
• 1207454-57-6 ethyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-95-9 (E)-6-fluoro-4-(4-fluorobenzylideneamino)isobenzofuran-1(3H)-one 
• 1322616-40-9 methyl 7-fluoro-2-(4-fluorophenyl)-1-hydroxy-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1322616-39-6 (E)-methyl 5-fluoro-2-(3-(4-fluorophenyl)-2-(1-methyl-1H-1,2,4-triazol-5-yl)acryloyl)-3-nitrobenzoate 
• 1322616-36-3 methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1322616-38-5 (E)-7-fluoro-5-(4-fluorobenzylideneamino)-4-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)phthalazin-1(2H)-one 
• 1322616-37-4 5-amino-7-fluoro-4-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)phthalazin-1(2H)-one 
• 1322616-34-1 (Z)-6-fluoro-3-((1-methyl-1H-1,2,4-triazol-5-yl)methylene)-4-nitroisobenzofuran-1(3H)-one 
• 1207453-90-4 6-fluoro-4-nitroisobenzofuran-1(3H)-one 

Relevant articles and documents

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA

Provided is a methods of treating multiple myeloma with inhibitors of poly(ADP-ribose)polymerase according to Formula (I):

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1 , R2 , R3 , R4 and R5 are as defined herein. Provided herein are inhibitors of poly (ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity